Tarsus Pharmaceuticals, INC Form 4 insider transactions

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, sold shares of common stock between March 18 and March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Tarsus Pharmaceuticals' CEO, Bobak R. Azamian, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reports the acquisition of common stock through the exercise of restricted stock units.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units.

General Counsel Wahl Bryan of Tarsus Pharmaceuticals reports the vesting and settlement of restricted stock units and shares acquired through the employee stock purchase plan.

Chief Operating Officer of Tarsus Pharmaceuticals, Seshadri Neervannan, reports the acquisition of 21,264 shares of common stock and the vesting of several tranches of Restricted Stock Units (RSUs).

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units and acquisition of shares through the employee stock purchase plan.

Director Andrew D. Goldberg exercised stock options in Tarsus Pharmaceuticals, increasing his beneficial ownership.

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs) on March 5, 2025.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units on March 5, 2025.

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Katherine Goodrich, a director at Tarsus Pharmaceuticals, acquired 10,000 stock options and 6,700 restricted stock units on November 13, 2024.

Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) in connection with her appointment.

Scott W. Morrison, a director at Tarsus Pharmaceuticals, transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust on September 30, 2024.

Director Scott W. Morrison of Tarsus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.

Director William J. Link reports disposals and distributions of Tarsus Pharmaceuticals shares, both directly and indirectly, through Flying L Partners XI, LLC and Link Family Enterprise, LP.

Director Rosemary A. Crane reports the acquisition of 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs) on June 24, 2024.

Director Andrew Goldberg reports the acquisition of 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs).

William Link, a director at Tarsus Pharmaceuticals, acquired 3,350 shares of common stock on June 24, 2024, through the settlement of vested Restricted Stock Units (RSUs).

Director Lin Elizabeth Yeu of Tarsus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.

Director Scott W. Morrison settled restricted stock units (RSUs) of Tarsus Pharmaceuticals, Inc. on June 24, 2024, acquiring 4,683 shares of common stock.

Director Bhaskar Chaudhuri reports the acquisition and disposal of Tarsus Pharmaceuticals common stock related to the settlement of vested Restricted Stock Units (RSUs).

Wendy L Yarno, a director of Tarsus Pharmaceuticals, reports the acquisition and disposal of common stock related to the settlement of restricted stock units.

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition and disposal of company stock related to the vesting and settlement of Restricted Stock Units (RSUs).